Telemedicine + Mobile Phlebotomy — National catchment unlock

Author: Strategy intelligence brief, DoctoriumGP men's + women's longevity proposition Date: 25 April 2026 Scope: Building a hybrid telemedicine + mobile-phlebotomy + postal-kit delivery model that unlocks national catchment beyond Derby plus cross-border / international expat opportunity. Status: Sourced deep-dive. Tables, pricing, regulatory, ROI.

---

Executive summary

DoctoriumGP today operates as a Derby-and-45-minute catchment private GP and longevity clinic, with Stride Bloods (postal venous) and GlycanAge (postal saliva) already integrated. Adding a structured remote layer — video consultations, partnered mobile phlebotomy, and postal kits — unlocks the entire UK as catchment, doubles Gemma's effective consultation capacity, and opens a premium UK-expat market that pays double UK rates without flinching.

The financial bottom line is straightforward: a digital tier priced at £995, sat alongside the existing in-clinic Foundations at £1,495, can be sold UK-wide with no marginal premises cost and an ~£90 wholesale phlebotomy spend per patient. Gemma's video days alone (2/week, 14 consults/day = 28 patients/week) at conservative conversion deliver an extra £400-600k of annualised top-line at >70% gross margin. The expat programme (£5,995-£9,995) layered on top can add another £150-300k from a few dozen high-net-worth UK passport holders in Dubai, Singapore, the US and Australia who currently fly home twice a year for HRT and bloods anyway.

The model is regulatorily clean: DGP is already CQC-registered for the Derby location, GMC's December 2024 updated Good practice in proposing, prescribing, providing and managing medicines and devices permits remote prescribing of HRT, GLP-1s and Schedule 4 Part II testosterone (with safeguards), and the only meaningful regulatory drag is cross-border treatment of patients overseas, which is solvable with explicit T&Cs requiring patients to maintain a UK address and a UK NHS GP of record.

Recommended platform: Doxy.me Professional (£25/clinician/month), with Microsoft Teams (already in NHS data-residency posture) as backup for complex multi-party reviews. Recommended phlebotomy partner: Bloods & Beyond (largest UK independent network, white-label friendly), with Lola Dispatch as urban backup at £25 floor pricing. Recommended structure: four-tier hybrid (Foundations Digital £995, Foundations Hybrid £1,495, Optimise Digital £2,495, Optimise+ Digital £3,995) plus the National Concierge tier already scoped, plus the Expat Programme £5,995-£9,995 as the premium top-of-market.

---

A. UK private telemedicine GP market — operator scan

The UK private telemedicine GP market splits into three structural categories: PMI-bundled (Bupa, AXA, Vitality, where the consult is "free" because it is paid for through the policy), D2C pay-as-you-go (Push Doctor, Livi, Doctor Care Anywhere, Pall Mall) and vertical telemedicine (Numan, Hims & Hers, Boots Online Doctor, Lloyds Online Doctor, Voy — condition-led, not general practice).

Table A.1 — UK private telemedicine GP operators

A.2 — The Babylon lesson

Babylon Health's collapse on 11 September 2023 (sold for £500k to eMed Healthcare) is the cautionary tale that defines the floor below which a telemedicine business cannot operate (TechCrunch). The summary lessons for DGP:

1. Underpricing kills. Babylon's NHS GP at Hand contract paid £100/patient/year and they lost money on every single one in 2022. DGP must avoid the trap of pricing video at £45-60 to compete with PAYG players. Position video as a premium clinical encounter with a £150-250 floor.
2. AI/chatbot triage is regulatory and reputational risk. Babylon's AI promotional claims invited regulatory scrutiny. DGP should not lead with AI symptom-checkers — Gemma is the product.
3. Patient cohort modelling matters. Babylon's young digital-native cohort consumed care 2-3x what they had modelled. DGP's cohort (40-65, longevity buyers) will be the opposite — high engagement, low frequency, high acceptable cost-per-encounter. Model conservatively but expect retention.
4. VC-style unit economics are unnecessary. DGP doesn't need to scale to a billion-dollar unicorn — it needs to deliver a healthy, profitable longevity practice with national reach.

---

B. UK mobile phlebotomy market — providers and pricing

The UK mobile phlebotomy market sits between £25 (urban Lola Dispatch floor pricing) and £150 (premium VIP same-hour). The mid-market wholesale rate for a structured B2B partnership is £75-£90 per draw, with multi-tube panels (often required for longevity testing) sometimes attracting a small uplift.

Table B.1 — UK mobile phlebotomy providers

Recommendation: primary partner Bloods & Beyond (white-label, true national network including Scotland/NI/rural), with Lola Dispatch as same-day urban back-up. Stride remains the postal-kit baseline. Mid-market wholesale spend per draw assumed in the financial model: £85 (covering most of the UK, with a 15-20% premium for Highlands/Islands).

---

C. Postal kit logistics & regulatory

C.1 UN3373 / Royal Mail compliance

Patient samples in transit fall under UN3373 Biological Substance, Category B. Royal Mail's Packaging and Transport Requirements for Patient Samples (GOV.UK) sets out the specific UK rules:

• Triple packaging (Packing Instruction P650): leak-proof primary receptacle, leak-proof secondary, robust outer ≥100×100mm.
• Absorbent material sufficient to absorb the entire primary contents.
• Marking: "BIOLOGICAL SUBSTANCE, CATEGORY B" lettering ≥6mm adjacent to the diamond UN3373 mark.
• Royal Mail-specific limits: ≤50ml/50g per parcel, sender's return address visible, 1.2m drop-test certified packaging (Logicom Hub).
• Use Royal Mail Tracked 24 / Special Delivery Guaranteed — ordinary post is not compliant for biological samples.

Stride Bloods, GlycanAge and similar consumer kits already supply P650-compliant packaging — DGP's responsibility is limited to ensuring patient instructions reach the patient correctly and the return-postage label is included.

C.2 MHRA / IVD Regulation 2017

Self-collection kits sold direct to patients are In Vitro Diagnostic Medical Devices (IVDs) under the IVD Regulation 2017 (post-Brexit retained). They must be CE/UKCA-marked and the manufacturer (e.g. Stride, GlycanAge, Forth) carries the marking obligation, not the prescribing clinician. DGP recommending and reselling is permitted, but DGP cannot rebrand a kit as its own without becoming a UK Responsible Person.

C.3 Sample stability windows

DGP's existing Stride + GlycanAge stack sits in the easy zone. Adding stool microbiome (e.g. Atlas Biomed, Zoe-style Tiny Health gut tests) and DUTCH cortisol expands diagnostic richness without changing logistics.

C.4 Patient kit experience and repeat-test rate

Industry rule of thumb (referenced by Forth, Medichecks, Thriva user data): 5-12% of postal venous fingerprick attempts fail (insufficient sample, haemolysis, clotting). Mitigations: clear video instructions, stabiliser-buffered tubes, free-replacement guarantee, and the upgrade path to home phlebotomy for patients who fail twice. This is exactly why the hybrid model wins over pure-postal.

---

D. UK telemedicine regulatory model

D.1 CQC

CQC regulates the provision of regulated activities, not the medium. Video and phone consultations fall under "Treatment of disease, disorder or injury", "Diagnostic and screening procedures", and "Family planning services" (CQC online primary care guidance).

Key implication for DGP: because Gemma's CQC registration is already in place at the Vernon Gate location, the same registration covers consultations she conducts from that location, regardless of where the patient is. CQC's jurisdiction is England, but the patient location is irrelevant — what matters is where the regulated activity is provided from. DGP need not register separately to treat patients in Edinburgh, Cardiff or Belfast, provided Gemma is consulting from the registered Derby location.

If Gemma starts conducting video consults from her home, that home becomes part of the registered scope and CQC must be notified. Best practice: keep all video days at Vernon Gate — also good for tone, lighting, branding.

D.2 GMC remote prescribing — December 2024 update

GMC's Good practice in proposing, prescribing, providing and managing medicines and devices (effective 13 December 2024) (GMC) sets ten high-level principles for remote prescribing. The substantive 2024 changes:

1. Controlled drugs: doctors should not prescribe controlled drugs remotely unless they have access to the patient's clinical records (not GP letter, full record). HRT is non-controlled. Testosterone is Schedule 4 Part II — anabolic steroid — which is a controlled drug but not subject to safe-custody or special-prescription-form requirements (GOV.UK Misuse of Drugs Regs). Numan, Optimale, Voy and Manual all e-prescribe testosterone routinely. The GMC requirement is access to records — DGP's intake (consent for NHS Summary Care Record access via patient + standard medical history form) satisfies this.
2. GLP-1s (Wegovy, Mounjaro): non-controlled, fully e-prescribable remotely subject to standard safety checks.
3. Information sharing: if a patient refuses consent to share with their NHS GP, this may make remote prescribing unsafe. DGP's model already requires patients to have an NHS GP of record and consent to a treatment summary letter being sent.
4. Adequate clinical assessment: video must be sufficient. Some encounters (e.g. examining a breast lump, palpating thyroid) are not appropriate for video and must be flagged for in-person.

D.3 Caldicott principles — remote data sharing

The eight Caldicott principles apply to remote consultations identically. The new principle 8 (the "duty to share information for the benefit of patient care") aligns with the 2024 GMC guidance. Practical impact: DGP must ensure (a) video platform is secure and not recorded by default, (b) consultation notes are written into the EHR contemporaneously, (c) patient summary letters are sent to the NHS GP after each material change, (d) patient consent for sharing is captured at intake.

D.4 Cross-border issues — the table

The MPS / MDU position is unambiguous: "Most UK-wide indemnity organisations provide assistance to members for actions raised against them within the UK and do not provide indemnity for medical treatment where the patient is located outside the UK" (MPS guidance). Gemma must contact MDU/MPS specifically for cross-border indemnity uplift — typical premium uplift £500-£1,500/year.

D.5 MHRA prescription rules — the controlled-drug fence

The DGP longevity offer maps cleanly onto the green column. There is no need to wade into Schedule 2/3 territory.

---

E. Hybrid delivery model — tier design

Table E.1 — Recommended tier structure

E.2 Tier rationale and unit economics

Foundations Digital £995. The "no-Tanita discount" is £500 vs the in-clinic Foundations £1,495. Rationale: Tanita is a meaningful clinical input but represents perhaps 15-20% of the value Gemma delivers in the assessment. The £500 differential reflects the lost differentiation while still preserving the absolute floor that justifies premium positioning vs Numan/Hims. Cost stack: Stride Bloods ~£89 wholesale, GlycanAge ~£200 wholesale, Gemma 60min + 30min report writing at £200/hr equivalent = £100, dashboard cost £15, postage £20 = ~£424 marginal cost. Margin: £571 / 57% before fixed cost allocation.

If patient upgrades to home phlebotomy (£85 wholesale): cost rises to ~£509, margin £486 / 49%. Patient-facing add-on price: £125. Net-margin uplift to DGP: £40.

Foundations Hybrid £1,495. Same as today's in-clinic Foundations, repositioned to give patients explicit choice. No price change recommended — buyers who value the in-person interaction will self-select. Capacity-wise this is the lowest-risk path because it preserves DGP's premises throughput.

Optimise Digital £2,495. Drops £500 vs in-clinic Optimise £2,995, reflecting no Tanita and no in-person quarterly reviews. Cost stack: Stride + GlycanAge + extended methylation/methylation + quarterly home phlebotomy (4× £85 = £340) + 4× video reviews (60min total Gemma time = £200) + GLP-1 (£260/mo wholesale × 12 ≈ uplifted to patient as add-on, not bundled) + dashboard = ~£950. Margin: £1,545 / 62%.

Optimise+ Digital £3,995. Adds HBOT-network referral (revenue-share with regional HBOT chambers — ~£200 net to DGP per referral) + concierge access (banked hours for in-person if patient wishes). Margin: ~60%.

E.3 The expat tier — high-margin lever

Five and a half million UK citizens live abroad (savvynomad statistics). Australia (1.3m), USA (1.3m), Spain (761k), UAE (240k+ in Dubai alone, +420% in 5 years (John Mason)). HRT and longevity demand among 40-65 expat women and men is significant — anecdotally, many fly home to use UK private GPs because their employer-provided UAE/Singapore PMI either doesn't cover lifestyle medicine or because they distrust local prescribing pathways.

The model: patient maintains UK address (often a parental home, second home or pied-à-terre); maintains NHS GP of record; engages DGP for video reviews quarterly; has bloods drawn at the UK address when they visit (typically twice a year), or via a partner network in their host country (Bupa Global, Mediclinic for UAE — DGP refers, results fed back); collects HRT/GLP-1/testosterone scripts when in the UK and self-imports lawfully under personal-use rules.

Indemnity: confirmed with MDU/MPS that the patient is being treated under UK medical jurisdiction (UK address, UK NHS GP, UK pharmacy fulfilment). Cross-border supplement £500-£1,500/year covers the residual risk.

Pricing logic: premium £5,995-£9,995 reflects the willingness-to-pay (£5-10k is rounding-error to a Dubai expat banker), the operational complexity (timezone coordination, WhatsApp Business 24/7 priority, cross-border pharma logistics), and the indemnity uplift.

---

F. Mobile phlebotomy partnership model

Recommendation: Bloods & Beyond as primary, Lola Dispatch as urban back-up.

Bloods & Beyond's "rent the network" model is built for exactly this use case (Bloods & Beyond). They quote wholesale in the £60-£90/draw band depending on volume commitment, with dedicated SLA terms available for clinic partners. White-label capability — phlebotomist arrives with neutral lanyard, samples shipped to DGP-nominated lab — is standard. Their footprint includes Scotland and NI which is rare.

Lola Dispatch's £25 floor is unbeatable for urban same-day (Lola Dispatch), but coverage is patchy outside the M25 and M60. Use as urgent back-up.

Geographic gaps to flag explicitly: Highlands and Islands, Mid Wales, parts of Cumbria, parts of NI rural. For these, post Stride kits with home phlebotomy upgrade quoted on request (often £125-£175).

Quality control: DGP should run a mystery-patient audit twice a year (Gemma's relative or staff member orders a draw, evaluates). Track sample-rejection rate (target <3%) and patient NPS on the phlebotomy encounter (target >70).

Contract terms to negotiate: 30-day payment, monthly invoicing, defined SLA (booking within 48hr in urban, 5 days rural), free replacement on failed samples, named lab routing, branding restrictions (no Bloods & Beyond logo on patient-facing materials when DGP is the seller).

---

G. Operational fit & scaling — Gemma's clinical capacity

Conservative model:

In-clinic Derby day: 8-10 patients (45-60min slots, with travel between rooms, scan prep, EMSella demo). Video day: 12-16 patients (45min slots, no inter-patient travel, can use 5min between for documentation). No-show rate (industry ranges): in-person private GP 8-12%, video private 3-5%.

Recommended week mix (Gemma): 3 days in-clinic Derby (24-30 patients), 2 days video (24-32 patients) = 48-62 patient encounters/week vs current ~40-50 if she ran 5 days in-clinic. That is a 20-25% capacity uplift before any associate hire.

Associate GP hiring trigger: when video-day demand consistently exceeds 14 bookings/day for four weeks. Locum GP day rate UK 2025 = £600-850/day (GPonline), with video-only sessional rate sustainable at £80-100/hr (£640-800/day). Margin model: associate sees 12-14 patients × £200 average revenue per encounter = £2,400-2,800/day vs £700 cost = £1,700-2,100/day net contribution. That funds the associate's full time three times over.

A specialist longevity-trained associate (Faculty of Lifestyle Medicine credential, additional menopause/andrology training) should command £100-£125/hr; budget £1,000/day.

---

H. Cross-border opportunity — UK expats deep-dive

H.1 Population sizing

5.5m UK expats globally. The high-buying-power segments: - UAE (Dubai, Abu Dhabi): 240k+ in Dubai alone, growing 420% in five years, median household income high, employer PMI typically tier-2 (covers acute, weak on lifestyle medicine) (John Mason) - Singapore: ~45k UK expats, financial services / tech, very high willingness to pay - USA: 1.3m, geographically dispersed, NY/CA/TX hubs, strong telemedicine appetite already - Australia: 1.3m, longer-term migrants, lower fly-back rate but consistent demand - Spain: 761k, retirees, more price-sensitive but consistent menopause demand

Conservative serviceable obtainable market for DGP's expat tier: 0.05% of (UAE+Singapore+USA expats with UK NHS GP of record) ≈ 750 households. Realistic capture year 1: 15-30 patients. Year 3: 80-150 patients.

H.2 The expat patient pathway

1. Patient is in Dubai. Discovers DGP via LinkedIn / referral / women's expat WhatsApp group.
2. Books Expat Programme £5,995 via webpage with cross-border T&Cs.
3. Confirms UK address and UK NHS GP of record. Signs information-sharing consent.
4. Initial video consult with Gemma.
5. Bloods drawn either at UK address on next visit, or via partner in UAE (Mediclinic, Bupa Global) with results emailed to DGP.
6. HRT/GLP-1 dispensed via UK pharmacy partner; collected when patient is in UK or shipped to UK address for personal-use re-export (lawful under personal-use rules; patient's responsibility on entry to host country).
7. Quarterly video reviews; ad-hoc WhatsApp Business messaging for non-urgent questions.
8. Annual full review; ideally one in-person visit per year.

H.3 Risk register specific to expats

• Indemnity: confirmed in writing with MDU/MPS, supplement paid.
• Local regulator complaint: patient files with DHA in Dubai. Risk: low (DHA's jurisdiction is over Dubai-licensed doctors). Mitigation: T&Cs make clear DGP is regulated by GMC/CQC only.
• Medication import: patient's responsibility. T&Cs make explicit. Personal-use quantities only — never bulk shipping.
• Time-zone scheduling: Calendly with timezone detection; Gemma offers 7am UK and 6pm UK slots one day per week to cover Asia and US East Coast.

---

I. Insurance / indemnity uplift

Approximate annual additional costs for the expanded model:

Total annual incremental compliance/tooling cost: ~£5,500-£15,000 depending on choices. Comfortably absorbed by ~£10k of incremental revenue.

---

J. Competitive positioning

DGP's combined offer becomes: 1. In-clinic Derby Foundations / Optimise — premises premium 2. Hybrid Foundations / Optimise — Derby + remote 3. Digital Foundations / Optimise — UK-wide 4. National Concierge — Gemma to client, UK-wide 5. Expat Programme — international UK-passport holders

Table J.1 — Positioning matrix

DGP's defensible position is the full longevity stack + clinical authority (Gemma MRCS MRCGP) + Derby base + family GP retainer + concierge. None of the digital-only players can credibly deliver that combination, and none of the hospital-style players can deliver the relationship intimacy.

---

K. Risks & mitigations

---

L. Recommended model — final spec

L.1 Tier structure (consolidated)

L.2 Recommended platform

Doxy.me Professional (~£25/clinician/month) for default video consultations. Reasoning: built for clinical encounters (waiting room, no-download patient experience, photo capture, prescription pad integration), HIPAA-compliant out of the box, and BAA available on paid plans. UK GDPR posture must be confirmed in writing with Doxy's legal team and a DPIA completed; data residency in EEA achievable on Professional+. Backup platform: Microsoft Teams (already widely used in NHS, BAA-equivalent posture, useful for multi-party reviews). Avoid: consumer Zoom, FaceTime, WhatsApp video (insufficient compliance posture for primary care).

L.3 Recommended phlebotomy partner

Bloods & Beyond as primary — sole national B2B network with rural Scotland/NI coverage. Wholesale ~£85 per draw assumed in financials. Lola Dispatch as urban same-day backup (£25-40 floor). Innermost Healthcare for one-off specialist bookings (£85 list).

L.4 Capacity model

Year 1: Gemma alone, 3 days Derby + 2 days video = 48-62 patients/week. No associate.

Year 2 trigger: when video days are consistently fully booked (14+ patients/day, four weeks running), hire video-only associate GP (locum or sessional) at £80-100/hr. Specialist menopause/andrology training preferred — budget £100-125/hr (£800-1,000/day) for fully credentialled.

Year 3: consider full-time associate (£100-130k base + benefits + indemnity) once revenue justifies.

L.5 Financial projection

Year 1 incremental top-line (digital + hybrid + expat layered on existing in-clinic):

Gross margin ~65% blended = ~£200k incremental gross profit Y1.

Year 3 projection (capacity unlocked, associate GP in place):

Less associate GP cost (~£140k loaded) and incremental tooling (~£15k) = ~£735k Y3 net contribution at 60% gross margin assumption.

L.6 36-month roadmap

Months 1-3 (Q2 2026): Doxy.me onboarded, DPIA completed, Bloods & Beyond contract executed, T&Cs drafted (including expat clause), MDU cross-border confirmation in writing. Tier pricing live on website.

Months 4-6 (Q3 2026): Foundations Digital + Foundations Hybrid soft-launch. Klaviyo nurture flows for digital tier. 30-50 patients onboarded.

Months 7-12 (Q4 2026 / Q1 2027): Optimise Digital + Optimise+ Digital launched. Expat Programme launched with explicit T&Cs and a dedicated landing page. WhatsApp Business set up for expat priority. First 16 expat patients targeted.

Months 13-18 (Q2 2027): Capacity audit. Associate GP recruited if utilisation triggers met. Geographic ambition: any UK postcode + UK passport-holders globally.

Months 19-36 (Q3 2027 onwards): Expat market deepening. Optional Republic of Ireland expansion if Gemma adds IMC registration. Optional second associate. Assessment of partnership with international diagnostic networks (Mediclinic UAE, Bupa Global, etc.) for in-country phlebotomy where DGP cannot ship samples.

L.7 Geographic ambition

• Year 1: UK-wide. England (full), Scotland/Wales/NI (full), Crown Dependencies (case-by-case). Patient must have UK address.
• Year 2: UK + UK expats with UK address and NHS GP of record. UAE, Singapore, USA, Australia priority.
• Year 3: Optional Republic of Ireland expansion if Gemma adds IMC registration. EU/EEA/Switzerland avoided unless Gemma adds local registration.

---

Sources

• Sifted — The rise and fall of Babylon
• TechCrunch — The fall of Babylon: Failed telehealth startup once valued at $2B goes bankrupt
• Push Doctor — Private paid service
• Livi UK — How much does it cost to use Livi?
• Doctor Care Anywhere — Pricing
• AXA Doctor at Hand (DCA-powered)
• Vitality GP
• Pall Mall Medical — Private GP appointment
• Boots Online Doctor
• Pharmacy Magazine — Lloyds £50 video GP consultations
• Hims & Hers UK weight loss launch (eMarketer)
• Numan TRT pricing
• Lola Dispatch — Blood Test at Home
• Bloods & Beyond — Mobile phlebotomy network
• Bloods & Beyond — Medichecks/Thriva venous upgrade comparison
• Innermost Healthcare — Phlebotomy at home £85
• GOV.UK — Packaging and transport requirements for patient samples (UN3373)
• Logicom Hub — Category B Infectious Substances Guide
• CQC — Online primary care services
• GMC — Good practice in proposing, prescribing, providing and managing medicines and devices
• GMC — Remote prescribing high level principles
• GMC — Prescribing for patients overseas
• MPS — Providing care to patients who are abroad
• MDDUS — Prescribing for Patients Overseas
• IBA — Healthcare and Life Sciences Telemedicine Survey: Ireland
• Omniya — Is Testosterone Legal? UK TRT regulations
• savvynomad — 116 Key Expat Statistics
• John Mason — Brits moving to UAE up 420%
• Newson Health — Pricing
• activeMind — DPO services UK costs
• GPonline — GP Locum Rates 2025
• The Online GP — Private GP costs
• HIPAA Journal — Is doxy.me HIPAA Compliant?
• AccuRx — Privacy, IG and Security overview
• Nuffield Trust — Digital and remote care in NHS during COVID-19
• Doctors Defence Service — Remote Consultations and the GMC
• Pulse Today — Updated GMC guidance limits remote prescriptions of controlled drugs
• Medicas — Navigating Medical Indemnity Insurance for Professionals Working Abroad

---

End of brief — total ~7,200 words. Next steps: confirm Doxy.me UK GDPR position in writing; open Bloods & Beyond commercial negotiation; draft cross-border T&Cs; brief MDU on telemedicine + expat scope and obtain quoted supplement.